Article Versions Notes

Krayem M, Sabbah M, Najem A, Wouters A, Lardon F, Simon S, Sales F, Journe F, Awada A, Ghanem GE, et al. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers. 2019; 11(8):1093. https://doi.org/10.3390/cancers11081093

Krayem, Mohammad, Malak Sabbah, Ahmad Najem, An Wouters, Filip Lardon, Stephane Simon, François Sales, Fabrice Journe, Ahmad Awada, Ghanem E. Ghanem, and et al. 2019. "The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma" Cancers 11, no. 8: 1093. https://doi.org/10.3390/cancers11081093

Krayem, M., Sabbah, M., Najem, A., Wouters, A., Lardon, F., Simon, S., Sales, F., Journe, F., Awada, A., Ghanem, G. E., & Van Gestel, D. (2019). The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers, 11(8), 1093. https://doi.org/10.3390/cancers11081093